

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

MF

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/039,789	03/16/98	CARVER	E 4537-01-2

 IM62/0413

ATTN: ANITA LOMARTRA
700 STATE STREET, GRANITE SQUARE
P.O. BOX 1960
NEW HAVEN CT 06509-1960

EXAMINER

SODERQUIST, A

ART UNIT	PAPER NUMBER
1743	16

DATE MAILED: 04/13/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary	Application No. 09/039,789	Applicant(s) Carver Jr. et al
	Examiner Arlen Soderquist	Group Art Unit 1743

Responsive to communication(s) filed on Feb 29, 2000.

This action is **FINAL**.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

Claim(s) 27-39 is/are pending in the application.

Of the above, claim(s) _____ is/are withdrawn from consideration.

Claim(s) _____ is/are allowed.

Claim(s) 27-39 is/are rejected.

Claim(s) _____ is/are objected to.

Claims _____ are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on _____ is/are objected to by the Examiner.

The proposed drawing correction, filed on _____ is approved disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All Some* None of the CERTIFIED copies of the priority documents have been

received.

received in Application No. (Series Code/Serial Number) _____.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____.

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

ARLEN SODERQUIST
PRIMARY EXAMINER

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

1. The amendment to claim 37 was not entered because there is not a claim 37 in the application.
2. The terminal disclaimer filed on August 9, 1999 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of Patent Number 5,728,351 has been reviewed and is NOT accepted.

It is directed to a particular claim or claims, which is not acceptable, since "the disclaimer must be of a terminal portion of the term of the entire [patent or] patent to be granted." See MPEP § 1490.

3. It is noted that the inventorship was changed in the parent application. Since the application was filed with a copy of the original declaration and there was no request to delete inventors, examiner is assuming that the instant inventorship includes two inventors.
4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
5. Claims 27 - 39 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Yamamoto in view of Kabata, Taylor, Dixon and Callan or Weiser (last three newly cited and applied). In the figures and associated discussion Yamamoto teaches an automated blood analyzer and method for making blood particle analyses. Yamamoto teaches at least one pump (102,111,162) in fluid communication with a mixing chamber (113-115) and a source diluent. A sample (101) is removed from a sample container by a sample probe (117,161) and the at least

one pump transfers the sample and diluent to the mixing chambers. Since the fluid flow arrows of figures 2 and 5 show pumps 102, 111, and 162 as capable of both suction and positive pressure, they are positive displacement pumps. Two different lysing reagents (141,142) are also transferred to the mixing chambers by a vacuum pump. The blood sample is analyzed for particles through a sensing orifice (158). The device has a controller (figure 3) for controlling the device and analyzing the result. Also Figure 4 shows that the result is obtainable in around 47 seconds. Yamamoto does not teach a multiple species database having different lysing compositions for each species which are mixed for blood samples from the different species.

In the paper Kabata teaches the analysis of the hematologic values of peripheral blood from normal adult rabbits using five different automated flow cytometers. During the analysis the software designed for human blood analysis was used. In the second paragraph of page 613 Kabata teaches that it is known that rabbit blood cells are known to differ from human blood cells in several aspects and suggests adapting the software for animal blood. Pages 614 - 615 discuss how the different automated systems work to obtain the various blood cell populations. It is noted that most of the automated systems incorporate a lysing reagent in the various methods. The rest of the article reports the results and discusses its significance. Of importance to the instant claims is the discussion on page 618 regarding the problems in determining the white blood cell differential counts. The first paragraph also teaches that the leukocytes of rabbits have several morphologic features that differ from human leukocytes. In the second to last paragraph Kabata teaches that automatic counting of **all** white blood cell sub-populations in animals would require different software. Also taught was the failure of Technicon software designed for use with rat or dog blood to give as reliable of results for rabbit blood as the software designed for humans. Since the Technicon software for rats and dogs give different results, the two sets of software are different.

In the paper Taylor compares several treatment procedures for preparing different cell populations for flow cytometric analysis. They teach that although each works, one of the methods works better than the others in flow cytometric analysis.

In the paper Dixon discusses electronic counting of dog leucocytes. In particular, the discrepancies arising from calibration with Coulter standard 4C and with the hemocytometer. The size distributions of leucocytes in canine blood and in standard 4C are markedly different. The use of 4C to calibrate Coulter counters may result in the selection of a threshold setting for canine leucocytes which is too high. Repeated hand counting may be used as a method of calibration, but regular discrepancies occur between hand and electronic counts which are attributable to the differing lytic actions of the diluents used, acetic acid having a more marked effect than commercial Zapoglobin. The degree of discrepancy between hand and electronic counts varied in individual dogs suggesting that there is an inconstant leucocyte subpopulation which behaves differently in response to different lytic agents. In the paragraph bridging the columns of page 252, Dixon teaches that canine leucocytes **did not show significantly increased lysis** when subjected to Zapoglobin at approximately four times the standard concentration, but did do so on exposure to the standard concentration for longer than five minutes. This is compared with results for bovine leukocytes **which did show a concentration dependent effect** to the lysing agent.

In the paper Callan evaluates an automated system for hemoglobin measurement in animals. The system was evaluated for its accuracy in measuring blood Hb concentration in animals by comparing it with standard techniques and for its suitability in veterinary practice. Blood samples, anticoagulated with potassium EDTA, from 78 healthy animals (33 dogs, 17 cats, 13 horses, and 15 cows) and 58 dogs and 4 cats with various blood abnormalities (10 anemia, 11 polycythemia, 21 lipemia, 16 leukocytosis, and 6 icterus) were analyzed. In all species, blood Hb concentration of healthy animals determined by the system was comparable to that measured by standard cyanmetHb methods (ie, an automated counter; $rI = 0.987$ to 0.998 and a Hb kit, $rI = 0.946$ to 0.993). In the second full paragraph of page 1763, Callan teaches that due to the variability between species an instrument would need to be calibrated for each species.

In the paper Weiser discusses the modification and evaluation of a multichannel blood cell counting system for blood analysis in veterinary hematology. The Coulter Counter Model S550 blood cell counting system was modified for use in veterinary hematology by increasing both the

erythrocyte and leukocyte aperture currents to 225 V and 195 V, respectively, followed by calibration with human blood. It was evaluated by use of 350 samples from dogs, cats, horses, and cows. Values for leukocyte count, erythrocyte count, mean corpuscular volume, and hematocrit generated by the S550 were compared with values generated by an automated multichannel counter with histogram capability and other reference procedures when appropriate. Mean differences for values between S550 and reference values were less than calibration tolerance limits for the instrument. Correlation coefficients were excellent for all values of each species. To assess behavior of leukocytes of the different species with respect to the counting threshold, leukocyte size distribution histograms were generated for all samples analyzed on the S550. Means for mean leukocyte volumes in diluent and lysing reagents were 55.5, 56.6, 67.4, and 72.8 fl for dogs, cats, horses, and cows, respectively. Canine leukocyte counts, because of small leukocyte size, were an average of 14% less for 5 samples analyzed on the unmodified instrument, compared with analysis after increasing the leukocyte aperture current. Leukocyte threshold failures attributable to interfering particles, resulting in falsely high counts, were recognized in 14%, 10%, 8% and 0% of feline, bovine, canine, and equine samples, respectively. The magnitude of error in these samples averaged 5% for cows and dogs, but was considered not important. However, leukocyte counts of feline samples in this group averaged 44% falsely high. In the last full paragraph of page 411, Weiser teaches that due to the variability between species leukocyte behavior in lysing reagent systems would need to be calibrated for each species.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate software/database for multiple species including differences in lytic agents as taught by Kabata into the Yamamoto device and method and control the device to perform the optimum process for each different species because one of ordinary skill in the art would have recognized that the utility of the device would be increased by the ability to process blood from multiple species and that due to differences in the morphology of the blood cells of the different species an optimized process including reagent sample compositions would have been required for each species as shown by Callan, Dixon, Taylor and Weiser.

6. Claims 27 - 39 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Cellect Hematology in view of Kabata, Taylor, Dixon and Callan or Weiser. In the figures and associated discussion Cellect Hematology teaches a fully automated blood analyzer and method for making blood particle analyses. In the figure on pages 5 - 6 Cellect Hematology shows the major systems of the instrument including at least one positive displacement syringe pump and stepper motor in fluid communication with a mixing chamber (dilution manifold) and a source diluent. A sample is removed from a sample container by a sample probe and the at least one pump transfers the sample and diluent to the dilution manifold. A lysing reagent is also provided during an analysis. The blood sample is analyzed for particles through a sensing orifice (counting manifold). The device has a controller (microprocessor) for controlling the device and analyzing the result. On page 1 in the first column, Cellect Hematology teaches the ease in adapting the instrument to add on new tests. Cellect Hematology does not teach a multiple species database having different lysing compositions for each species which are mixed for blood samples from the different species.

In the paper Kabata teaches the analysis of the hematologic values of peripheral blood from normal adult rabbits using five different automated flow cytometers. During the analysis the software designed for human blood analysis was used. In the second paragraph of page 613 Kabata teaches that it is known that rabbit blood cells are known to differ from human blood cells in several aspects and suggests adapting the software for animal blood. Pages 614 - 615 discuss how the different automated systems work to obtain the various blood cell populations. It is noted that most of the automated systems incorporate a lysing reagent in the various methods. The rest of the article reports the results and discusses its significance. Of importance to the instant claims is the discussion on page 618 regarding the problems in determining the white blood cell differential counts. The first paragraph also teaches that the leukocytes of rabbits have several morphologic features that differ from human leukocytes. In the second to last paragraph Kabata teaches that automatic counting of **all** white blood cell sub-populations in animals would require different software. Also taught was the failure of Technicon software designed for use with rat or dog blood to give as reliable of results for rabbit blood as the software designed for

humans. Since the Technicon software for rats and dogs give different results, the two sets of software are different.

In the paper Taylor compares several treatment procedures for preparing different cell populations for flow cytometric analysis. They teach that although each works, one of the methods works better than the others in flow cytometric analysis.

In the paper Dixon discusses electronic counting of dog leucocytes. In particular, the discrepancies arising from calibration with Coulter standard 4C and with the hemocytometer. The size distributions of leucocytes in canine blood and in standard 4C are markedly different. The use of 4C to calibrate Coulter counters may result in the selection of a threshold setting for canine leucocytes which is too high. Repeated hand counting may be used as a method of calibration, but regular discrepancies occur between hand and electronic counts which are attributable to the differing lytic actions of the diluents used, acetic acid having a more marked effect than commercial Zapoglobin. The degree of discrepancy between hand and electronic counts varied in individual dogs suggesting that there is an inconstant leucocyte subpopulation which behaves differently in response to different lytic agents. In the paragraph bridging the columns of page 252, Dixon teaches that canine leucocytes **did not show significantly increased lysis** when subjected to Zapoglobin at approximately four times the standard concentration, but did do so on exposure to the standard concentration for longer than five minutes. This is compared with results for bovine leukocytes **which did show a concentration dependent effect** to the lysing agent.

In the paper Callan evaluates an automated system for hemoglobin measurement in animals. The system was evaluated for its accuracy in measuring blood Hb concentration in animals by comparing it with standard techniques and for its suitability in veterinary practice. Blood samples, anticoagulated with potassium EDTA, from 78 healthy animals (33 dogs, 17 cats, 13 horses, and 15 cows) and 58 dogs and 4 cats with various blood abnormalities (10 anemia, 11 polycythemia, 21 lipemia, 16 leukocytosis, and 6 icterus) were analyzed. In all species, blood Hb concentration of healthy animals determined by the system was comparable to that measured by standard cyanmetHb methods (ie, an automated counter; $rI = 0.987$ to 0.998 and a Hb kit, $rI =$

0.946 to 0.993). In the second full paragraph of page 1763, Callan teaches that due to the variability between species an instrument would need to be calibrated for each species.

In the paper Weiser discusses the modification and evaluation of a multichannel blood cell counting system for blood analysis in veterinary hematology. The Coulter Counter Model S550 blood cell counting system was modified for use in veterinary hematology by increasing both the erythrocyte and leukocyte aperture currents to 225 V and 195 V, respectively, followed by calibration with human blood. It was evaluated by use of 350 samples from dogs, cats, horses, and cows. Values for leukocyte count, erythrocyte count, mean corpuscular volume, and hematocrit generated by the S550 were compared with values generated by an automated multichannel counter with histogram capability and other reference procedures when appropriate. Mean differences for values between S550 and reference values were less than calibration tolerance limits for the instrument. Correlation coefficients were excellent for all values of each species. To assess behavior of leukocytes of the different species with respect to the counting threshold, leukocyte size distribution histograms were generated for all samples analyzed on the S550. Means for mean leukocyte volumes in diluent and lysing reagents were 55.5, 56.6, 67.4, and 72.8 fl for dogs, cats, horses, and cows, respectively. Canine leukocyte counts, because of small leukocyte size, were an average of 14% less for 5 samples analyzed on the unmodified instrument, compared with analysis after increasing the leukocyte aperture current. Leukocyte threshold failures attributable to interfering particles, resulting in falsely high counts, were recognized in 14%, 10%, 8% and 0% of feline, bovine, canine, and equine samples, respectively. The magnitude of error in these samples averaged 5% for cows and dogs, but was considered not important. However, leukocyte counts of feline samples in this group averaged 44% falsely high. In the last full paragraph of page 411, Weiser teaches that due to the variability between species leukocyte behavior in lysing reagent systems would need to be calibrated for each species.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate software/database for multiple species including differences in lytic agents as taught by Kabata into the Cellect Hematology method and device and control the device to perform the optimum process for each different species because one of ordinary skill in the art

would have recognized that the utility of the device would be increased by the ability to process blood from multiple species and that due to differences in the morphology of the blood cells of the different species an optimized process including reagent sample compositions would have been required for each species as shown by Callan, Dixon, Taylor and Weiser.

7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

8. Claims 35 and 38-39 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 11 - 14 of U.S. Patent No. 5,728,351.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims totally encompass the patented claims.

9. Applicant's arguments filed February 29, 2000 have been fully considered but they are not persuasive. Relative to the arguments applicant is reminded that there is no requirement as to what the operator's input is in the claims. Thus the input could be one telling the volume of lysing agent to add. Examiner is not sure, but such information should be present in the ability of an instrument to set up to run the analysis as lysing agents are changed. This has nothing to do with a species related input in which the apparatus determines the volume based on an input of the animal species in a sample. Therefore any arguments related to inputting a species type into the apparatus are not commensurate in scope with the independent claims. Also contrary to what applicant argues, the Dixon reference does teach something critically important to the obviousness of the claims for which a species type is the input. As set forth above the Dixon reference is clear that there is a concentration dependent efficacy of a lysing agent in some species. This certainly

would have motivated one of skill in the art to be concerned with the concentration of a lysing agent as the species of blood changes. This would have also given an expectation that different species may require a different concentration of a lysing agent for optimal performance. This would have motivated one of skill in the art to determine effective concentration ranges for a lysing agent to be used with more than one animal species. The additional references add further indications or expectations that the blood from different species are different and must be treated differently in a flow analysis as taught by the Cellect Hematology or Yamamoto references. Relative to the submission of a terminal disclaimer if applicant elects to file an appeal in this application, a proper terminal disclaimer must be filed prior to the Appeal Brief in order to be held as timely filed.

10. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

11. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The cited art relates to measuring properties of animal blood.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arlen Soderquist whose telephone number is (703) 308-3989. The examiner can normally be reached Monday through Thursday and some Fridays from about 7:30 AM to about 5:00 PM.

For communication by fax to the organization where this application or proceeding is assigned, (703) 305-7719 may be used for official, unofficial or draft papers. When using this number a call to alert the examiner would be appreciated. Another number for official papers is

(703) 305-3599. The above fax numbers will generally allow the papers to be forwarded to the examiner in a timely manner.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0661.



April 12, 2000

ARLEN SODERQUIST
PRIMARY EXAMINER